M. Andriani et al., RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR (RT-PA) AS FIRST-LINE THERAPY FOR DECLOTTING OF HEMODIALYSIS ACCESS, Nephrology, dialysis, transplantation, 10(9), 1995, pp. 1714-1719
One of the most common complication in haemodialysis patients is throm
bosis of the arteriovenous fistula (AVF). Thirty-five patients with a
total of 42 thromboses of the angioaccess were infused via a small nee
dle: (i) into the feeding artery (50% of the cases); (ii) into a AVF v
enous segment of the arteriovenous fistula (42.8%); (iii) directly int
o the thrombus (7.1%), by rt-PA. After an initial pulse of 5 - 10 mg,
according to body weight, the drug was continuously infused by a pump
with the speed automatically programmed in 30 Brescia-Cimino autologou
s AV fistulae and 12 polytetrafluoroethylene (PTFE) grafts. A complete
thrombolysis with return of bruit and thrill was obtained in 71.4% of
the cases using a mean drug dose of 21 mg and an infusion time of 3.8
h. All the successful cases underwent haemodialysis via AVF on the sa
me day. No bleeding occurred at remote sites. Local bleeding occurred
in 16% of the cases; in no case was it so severe as to require the sus
pension of the therapy or blood transfusions. The median cumulative du
ration of patency after thrombolysis was 32.4 months. Respectively 21,
12 and two patients had a functioning angioaccess after 3.6, 32.4 and
36 months from the lytic approach. Failure of the treatment was not r
elated to the patients' gender or age, AVF age, route of administratio
n of the drug, type of vessel (natural or artificial), or delay betwee
n the discovery of the fistula occlusion and the start of the therapy.
In unsuccessful cases an organic lesion of the vessels was documented
by angiography or echo colour Doppler. In summary, rt-PA local infusi
on provides a useful means of preservation of AV fistulae and may be u
sed as the therapy of first choice in dialysis patients without active
bleeding or high bleeding risk.